Tonix Pharmaceut Stock Price, News & Analysis

Tonix Pharmaceuticals (Nasdaq: TNXP) announced a poster presentation at the Neuroscience 2022 conference, scheduled for November 12-16, 2022, in San Diego. The presentation, titled “In Vitro Impact of Oxytocin on Human Sensory Neurons”, will occur on November 14, 2022, from 1:00 p.m. to 2:00 p.m. PT. Notable authors include Dr. David C. Yeomans from Stanford University and Tonix's Dr. David Hsu. The company continues to develop therapeutics for various conditions, with ongoing studies for fibromyalgia and Long COVID, while maintaining a focus on CNS, rare diseases, and immunology.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) reported third-quarter financial results for 2022, revealing cash and equivalents of $140 million. The company is advancing its pipeline, with a Phase 3 study for TNX-102 SL in fibromyalgia underway, and a Phase 2 study for Long COVID expected to show interim data in Q2 2023. R&D expenses rose to $22.2 million, driven by increased clinical activities, leading to a net loss of $29 million, or $0.69 per share. Tonix's diverse pipeline targets CNS disorders, rare diseases, and infectious diseases, with several trials anticipated to start soon.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that COO Jessica Morris will present at BioFuture on November 8, 2022, at 11:00 a.m. ET, at the Lotte New York Palace. During the event, she will host investor meetings. Interested investors can register for meetings via the BioFuture website. Tonix is focused on developing therapeutics for CNS, rare diseases, immunology, and infectious diseases, with key candidates in advanced stages, including TNX-102 SL for fibromyalgia and TNX-1300 for cocaine intoxication.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has entered a securities purchase agreement with institutional investors for 1,400,000 shares of Series A convertible redeemable preferred stock and 100,000 shares of Series B preferred stock at a price of $9.50 per share. This pricing reflects a 5% discount to the stated value of $10.00. The total gross proceeds from this offering are expected to be $15 million. The closing is anticipated on or about October 26, 2022, subject to customary conditions.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that Jessica Morris, COO, will present at the ThinkEquity Conference on October 26, 2022, at 10:30 a.m. ET in New York City. Investors can arrange meetings with the company's management via the conference coordinator. A webcast will be available on Tonix's website. Tonix focuses on developing therapeutics for various diseases including fibromyalgia and Long COVID, with several product candidates in different stages of clinical development. Key upcoming studies are expected in 2023 for multiple candidates, including TNX-1300 and TNX-601 ER.

Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman will hold one-on-one meetings at the BIO-Europe Conference in Leipzig, Germany, from October 24-26, 2022. The conference presentation will be available to registered participants. Tonix focuses on developing therapeutics for CNS, rare diseases, immunology, and infectious diseases. Their lead candidate, TNX-102 SL, is in mid-Phase 3 trials for fibromyalgia and also targets Long COVID. Upcoming studies include TNX-1300 for cocaine intoxication and TNX-601 ER for major depressive disorder.

Tonix Pharmaceuticals (Nasdaq: TNXP) announced FDA clearance for its IND application for TNX-601 ER, an extended-release tablet for major depressive disorder (MDD). The Phase 2 clinical trial is set to begin in Q1 2023, evaluating the efficacy and safety of the once-daily formulation. Tianeptine, already available in other countries for over 30 years, offers a unique mechanism of action distinct from traditional antidepressants, potentially exhibiting fewer side effects. TNX-601 ER also incorporates abuse-deterrent properties, aimed at minimizing misuse risks associated with tianeptine.

Tonix Pharmaceuticals (Nasdaq: TNXP) presented a study at the IASP 2022 World Congress on Pain about Long COVID symptoms. The research found that approximately 40% of Long COVID patients experience fibromyalgia-like multi-site pain. Furthermore, 50% of those with multi-site pain and sleep disturbances are using opioids for relief, highlighting a significant public health concern. Tonix is developing TNX-102 SL as a non-opioid treatment for these patients, with ongoing Phase 2 trials expected to provide interim results in early 2023.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced promising results from studies on its TNX-1500 monoclonal antibody at the 29th International Congress of The Transplantation Society. The research demonstrated TNX-1500's effectiveness in preventing organ rejection in non-human primates, showing 'long-term rejection-free survival' for both allograft and xenograft transplants. The company plans to start a Phase 1 trial in the first half of 2023, indicating potential for TNX-1500 to address significant needs in organ transplant rejection treatment.